This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
4 Hospital Stocks to Gain From Rebounding Patient Volumes
by Zacks Equity Research
Expanding patient volumes, use of telehealth services, cost-control measures and an aging demography are tailwinds to the hospital industry players like HCA, UHS, THC and ACHC.
Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXH
Community Health's (CYH) Q3 Earnings Beat, Improve Y/Y
by Zacks Equity Research
Community Health's (CYH) third-quarter earnings gain from a solid revenue stream and lower expenses.
Molina Healthcare's (MOH) Q3 Earnings Beat Mark, Fall Y/Y
by Zacks Equity Research
Molina Healthcare (MOH) Q3 earnings gain from better revenues, partly offset by steep expenses.
Ensign Group (ENSG) Q3 Earnings Meet, '21 Earnings Guidance Up
by Zacks Equity Research
Ensign Group's (ENSG) third-quarter earnings gain from improved revenues, partly offset by steep expenses.
Teladoc Health (TDOC) Q3 Loss Narrower Than Expected, Down Y/Y
by Zacks Equity Research
Teladoc Health's (TDOC) third-quarter results indicate improved revenues owing to higher access fees and visit fees, partly offset by elevated costs.
LabCorp (LH) Q3 Earnings Surpass Estimates, 2021 View Up
by Zacks Equity Research
LabCorp's (LH) Q3 Diagnostics revenues get significantly impacted by drop in sales for COVID-19 testing.
Encompass Health (EHC) Misses on Q3 Earnings, Cuts '21 EPS View
by Zacks Equity Research
Encompass Health's (EHC) third-quarter earnings miss estimates but improve year over year on the back of top-line growth resulting from a sound Inpatient Rehabilitation segment.
CONMED's (CNMD) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
CONMED's (CNMD) third-quarter earnings reflect strong segmental performance.
West Pharmaceutical (WST) Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
West Pharmaceutical's (WST) third-quarter earnings reflect segmental strong performance.
Align Technology (ALGN) Q3 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Continued momentum in Invisalign Clear Aligners and iTero scanners sales volumes drove Align Technology's (ALGN) revenues during the third quarter.
Edwards Lifesciences (EW) Beats on Q3 Earnings, Gross Margin Up
by Zacks Equity Research
Strong sales growth across all four products group along with increased adoption of the PASCAL platform drove Edwards Lifesciences' (EW) third-quarter revenues.
Thermo Fisher (TMO) Beats on Q3 Earnings, Raises 2021 View
by Zacks Equity Research
Thermo Fisher (TMO) delivers a strong quarterly performance, leveraging on a significant rebound in its base business.
Boston Scientific (BSX) Q3 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Barring CRM, Boston Scientific's (BSX) organic revenues at each of its core business segments and geographies increase in Q3.
Masimo's (MASI) Q3 Earnings Surpass Estimates, '21 View Up
by Zacks Equity Research
Masimo's (MASI) robust product shipments, along with strong sensor sales, drive its Q3 sales.
Universal Health (UHS) Q3 Earnings Miss Mark, Decline Y/Y
by Zacks Equity Research
Universal Health's (UHS) third-quarter results reflect high expenses, partly offset by better revenues.
Ecolab (ECL) Q3 Earnings & Revenues Beat Mark, Margins Down
by Zacks Equity Research
Ecolab's (ECL) robust performance across the majority of its segments drives its Q3 sales despite pandemic-led business challenges.
Centene's (CNC) Q3 Earnings Miss Estimates, Revenues Up Y/Y
by Zacks Equity Research
Centene's (CNC) third-quarter results reflect improved revenues, better Medicare and Medicaid membership growth, partly offset by higher SG&A costs.
4 Healthcare Stocks to Top Q3 Estimates Amid Coronavirus Woes
by Srijita Guha
Factors like an aging populace and demand for products and services are likely to reflect on the Q3 results of ACAD, MD, ACHC and VRTX.
HCA Healthcare (HCA) Q3 Earnings Beat Estimates, Surge Y/Y
by Zacks Equity Research
HCA Healthcare's (HCA) Q3 earnings results reflect gains from patient volumes and better revenues.
HCA Healthcare (HCA) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
HCA (HCA) delivered earnings and revenue surprises of 11.46% and 4.65%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?
by Zacks Equity Research
Sector ETF report for FXH
Should You Buy HCA Healthcare (HCA) Ahead of Earnings?
by Zacks Equity Research
HCA Healthcare (HCA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
What's in Store for HCA Healthcare's (HCA) Q3 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) Q3 results are likely to reflect better revenues owing to higher patient volumes.
HCA Healthcare (HCA) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
HCA (HCA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.